Literature DB >> 9439479

Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima.

V V Tertov1, A N Orekhov.   

Abstract

The subfraction of low density lipoprotein (LDL) with low sialic acid content that caused accumulation of cholesterol esters in human aortic smooth muscle cells has been found in the blood of coronary atherosclerosis patients. It was demonstrated that this subfraction consists of LDL with small size, high electronegative charge, reduced lipid content, altered tertiary structure of apolipoprotein B, etc. LDL of this subfraction is naturally occurring multiple-modified LDL (nomLDL). In this study we compared the binding, uptake and proteolytic degradation of native LDL and nomLDL by smooth muscle cells cultured from human grossly normal intima, fatty streaks, and atherosclerotic plaques. Uptake of nomLDL by normal and atherosclerotic cells was 3.5- and 6-fold, respectively, higher than uptake of native LDL. Increased uptake of nomLDL was due to increased binding of this LDL by intimal smooth muscle cells. The enhanced binding is explained by the interaction of nomLDL with cellular receptors other than LDL-receptor. Modified LDL interacted with the scavenger receptor, asialoglycoprotein receptor, and also with cell surface proteoglycans. Rates of degradation of nomLDL were 1.5- and 5-fold lower than degradation of native LDL by normal and atherosclerotic cells, respectively. A low rate of nomLDL degradation was also demonstrated in homogenates of intimal cells. Activities of lysosomal proteinases of atherosclerotic cells were decreased compared with normal cells. Pepstatin A, a cathepsin D inhibitor, completely inhibited lipoprotein degradation, while serine, thiol, or metallo-proteinase inhibitors had partial effect. This fact reveals that cathepsin D is involved in initial stages of apoB degradation by intimal smooth muscle cells. Obtained data show that increased uptake and decreased lysosomal degradation of nomLDL may be the main cause of LDL accumulation in human aortic smooth muscle cells, leading to foam cell formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9439479     DOI: 10.1006/exmp.1997.2216

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  13 in total

1.  Cathepsin B: Basis Sequence: Mouse.

Authors:  Dora Cavallo-Medved; Kamiar Moin; Bonnie Sloane
Journal:  AFCS Nat Mol Pages       Date:  2011-04-10

Review 2.  Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.

Authors:  Yanwen Qin; Guo-Ping Shi
Journal:  Pharmacol Ther       Date:  2011-05-12       Impact factor: 12.310

3.  Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Sofia Jormsjö; Dirk M Wuttge; Allan Sirsjö; Carl Whatling; Anders Hamsten; Sten Stemme; Per Eriksson
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

4.  Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy.

Authors:  Alexander N Orekhov; Igor A Sobenin; Mikhail A Gavrilin; Alexei Gratchev; Svetlana Y Kotyashova; Nikita G Nikiforov; Julia Kzhyshkowska
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

5.  Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague⁻Dawley Rats .

Authors:  Princy Khurana; Tulasi Yadati; Sandeep Goyal; Atul Dolas; Tom Houben; Yvonne Oligschlaeger; Anil K Agarwal; Aditya Kulkarni; Ronit Shiri-Sverdlov
Journal:  Biomolecules       Date:  2019-05-04

6.  One-Year Conservative Care Using Sodium Bicarbonate Supplementation Is Associated with a Decrease in Electronegative LDL in Chronic Kidney Disease Patients: A Pilot Study.

Authors:  Felipe Rizzetto; Denise Mafra; Ana Beatriz Barra; Gisella Pires de Melo; Dulcinéia Saes Parra Abdalla; Maurilo Leite
Journal:  Cardiorenal Med       Date:  2017-08-17       Impact factor: 2.041

7.  Altered gene expression in early atherosclerosis is blocked by low level apolipoprotein E.

Authors:  Yanqing Ma; Craig C Malbon; David L Williams; Fayanne E Thorngate
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

Review 8.  Development of Antiatherosclerotic Drugs on the basis of Natural Products Using Cell Model Approach.

Authors:  Alexander N Orekhov; Igor A Sobenin; Victor V Revin; Yuri V Bobryshev
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

9.  Approach to reduction of blood atherogenicity.

Authors:  Alexander N Orekhov; Alexandra A Melnichenko; Igor A Sobenin
Journal:  Oxid Med Cell Longev       Date:  2014-06-29       Impact factor: 6.543

Review 10.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.